Before answering this important question, I think that we, as Radiation Oncologists, should give serious consideration to moving past the terminology of "bridging radiation therapy" and instead refer to it as "pre-CAR-T infusion radiation therapy." Bridging therapy was initially an apt name; we were...

Bridging radiotherapy is appropriate/beneficial for patients who present with: Rapidly progressive disease that needs to be controlled during the CAR-T manufacturing period (3-6 weeks). Lymphoma at this stage is chemoresistant but radiosensitive. There are studies that show bridging radiotherapy to...